08:36 AM EST, 02/11/2026 (MT Newswires) -- Labcorp Holdings ( LH ) said Wednesday that it has launched nationwide access to the Elecsys pTau-181 test, a US Food and Drug Administration-cleared blood test designed to aid the initial assessment of Alzheimer's disease in primary care.

The test, developed by Roche Diagnostics and cleared by FDA last year, helps rule out Alzheimer's in symptomatic patients aged 55 and older by identifying those who are unlikely to have amyloid pathology, the company said.

Labcorp ( LH ) said the test has a negative predictive value of 97.9% and is performed through a routine blood draw at a physician's office or any of its more than 2,200 patient service centers.